# NEXT SESSION — BD Platform

**Written:** 2026-05-23 (updated after Session 14)  
**Session focus:** Rule E5 — Drug Identity Completeness; Structural integrity now fully enforced across 4 invariants

---

## Session 14 Summary

### ✅ Rule E5: Drug Identity Completeness — Enforced
- Invariant: every drug with a `drug_areas` row must have non-null: `display_name` (or `name`), `company_id`, `target`, `stage`, `catalog_category`
- New test type `drug_identity_check` added to `validate_ground_truth.py`
- 5 blocking gaps found and patched:
  - `miv-cel` → target=CD19, catalog_category=Oncology (was Pipeline — CAR-T correction)
  - `cln-978` → target=CD19, display_name=CLN-978, catalog_category=Oncology
  - `orilanolimab` → target=FcRn (inferred from anti-FcRn mAb modality)
  - `lm-302` → catalog_category=Oncology (CLDN18.2 MMAE-ADC)
  - `gb004` → catalog_category=Small Molecule (oral PHD inhibitor)
- 470 Rule E5 tests seeded (94 drugs × 5 fields)
- **Validation: 240 → 710/710 passing**

### ✅ Structural Integrity — All 4 Invariants Now Enforced

| Rule | Test Type | Tests | Invariant |
|------|-----------|-------|-----------|
| E1 (DKN visibility) | `catalog_visibility` | ~94 | drug with drug_areas → catalog_category not null |
| E3 (company_area consistency) | `company_area_check` | 61 | company_profiles row → company_areas row exists |
| E4 (drug score consistency) | `drug_area_score_check` | 96 | drug_area_scores row → drug_areas row exists |
| E5 (drug identity completeness) | `drug_identity_check` | 470 | drug with drug_areas → all identity fields not null |

---

## P0 — Next Session Priorities

| Priority | Task | Effort |
|----------|------|--------|
| P1 | **Wire E3/E4/E5 into write paths** — `quick_profiles_enrich.py` should ensure `company_areas` exists before writing profile; `approve_discovery.py` should ensure `drug_areas` exists before writing score; `company_enrichment.py` drug insert should assert `target` + `stage` non-null | Low |
| P1 | **Run full company_enrichment.py for UCB/tcell** — quick_profiles done; drug-level summaries, mol_intel, and overlap not yet enriched | Medium |
| P2 | **Expand area coverage for Lilly/Pfizer** — verify all company_areas present, then enrich remaining areas via quick_profiles_enrich.py | Low |
| P2 | **Rule E2: drug_area_scores completeness** — every drug_areas row must have a drug_area_scores row with overlap + confidence_level set | Medium |
| P3 | **24 advisory gaps: canonical_drug_id** — 24 area-linked drugs have no canonical_drug_id. Address in a canonical entity resolution sprint. | Medium |
| P3 | **Migrate tl1aPI static JS object to Supabase** | High effort, high long-term value |

---

## Architecture State (as of 2026-05-23 Session 14)

```
DB (Supabase):
  enrichment_runs         ← live (v16 applied)
  drugs                   ← live; 143 rows; all 94 area-linked drugs have complete identity
  drug_area_scores        ← live; 96 rows (clean — all have matching drug_areas)
  drug_areas              ← live; 179+ rows
  company_profiles        ← live; 37/60 enriched
  company_areas           ← live; clean — all profiles have matching company_areas
  validation_tests        ← live; 710 tests, all passing
  catalysts               ← live; Roche dedup pending
  molecule_intelligence   ← live; 51 records; ~12 uncovered TL1A drugs remain

UI (GitHub Pages):
  Entity dossier          ← live; confidence badges active
  Company dossier         ← live; 5 tabs
  Drug dossier            ← live; 3 tabs
```

---

## Known Issues

| Issue | Severity | Status |
|-------|----------|--------|
| 24 drugs missing canonical_drug_id | Low | Advisory only; older drugs without canonical IDs. Will fix in entity resolution sprint. |
| drug_areas rows without drug_area_scores (Rule E2) | Medium | Not yet audited. Next structural invariant to enforce. |
| Roche catalyst near-duplicates (~10) | Medium | AMETRINE ×3, QX031N ×4 — needs dedup sprint |
| ensure_canonical_id() doesn't insert into canonical_drugs | Medium | Workaround applied; fix when running next mol_intel batch |
| ~12 TL1A drugs with no mol_intel | Low | Lower priority; fix ensure_canonical_id first |
| Confidence badges show '?' | Low | Resolves as enrichment populates source_url |

---

## Quick Reference

**Run validation suite:**
```bash
cd "/sessions/wonderful-dazzling-pasteur/mnt/BD Platform"
SUPABASE_SERVICE_KEY=$(cat .supabase_service_key) python3 scripts/validate_ground_truth.py
```

**Run company profile enrichment:**
```bash
ANTHROPIC_API_KEY=$(cat .anthropic_api_key) \
SUPABASE_SERVICE_KEY=$(cat .supabase_service_key) \
python3 scripts/quick_profiles_enrich.py --area tcell --company ucb
```

**Deploy to GitHub Pages:**
```bash
WS="/sessions/wonderful-dazzling-pasteur/mnt/BD Platform"
TMP=$(mktemp -d)
TOKEN=$(cat "$WS/.github_token")
git clone "https://$TOKEN@github.com/kyleklaassen-dev/bd-dashboard.git" "$TMP"
cp "$WS/index.html" "$TMP/index.html"
cd "$TMP" && git add index.html && git commit -m "..." && git push
```

**Supabase REST PATCH:**
```bash
KEY=$(cat "$WS/.supabase_service_key")
curl -s -X PATCH "https://tghntyofptvfhmtchwcv.supabase.co/rest/v1/drugs?id=eq.DRUG_ID" \
  -H "apikey: $KEY" -H "Authorization: Bearer $KEY" \
  -H "Content-Type: application/json" -H "Prefer: return=minimal" \
  -d '{"field": "value"}'
```
